La vendita allo scoperto per Cellectar Biosciences dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Cellectar Biosciences. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Cellectar Biosciences (NASDAQ:CLRB) Azioni, Report sulle vendite allo scoperto

Cellectar Biosciences

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences Inc

News

CLRB

Cellectar Biosciences Signs Supply Agreement With NorthStar Medical Radioisotopes; NorthStar To Provide Co. With Non-Carrier Added Ac-225 For Its Clinical Programs

<a href="https://www.globenewswire.com/Tracker?data=sWiYCqh2uCQMJWzqp6DwsdmQh3T4XTg8U-EKXY44n4hZiPT9dDAL2XxpEGQuQ0_FLftN717tZtO31l7Vu9ABlg==">SpectronRx,</a>&nbsp;a leading radiopharmaceutical contract developer and manufacturer, and <a href="https://www.globenewswire.com/Tracker?data=vf-DqZeYBelFzXaBVMAW0zNzKNSEr5kVaMsaca_-3bQ_x24bx0xUhAaFSEZk7GfZQBG6R463oTmmB2-PVadf2n3jqJSFu3yMiwiBy5adA8eByjtpC0MvAD8joOcqYop4">Cellectar Biosciences, Inc. (NASDAQ:</a><a href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, have signed a commercial supply agreement for the manufacture of Cellectar's first-in-class cancer therapy, iopofosine I 131.

Biotech

General

Cellectar Biosciences And SpectronRx Have Signed A Commercial Supply Agreement For The Manufacture Of Cellectar's First-In-Class Cancer Therapy, Iopofosine I 131

Cellectar Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>), a late-stage clinical biopharmaceutical company, announced today it received a letter dated October 31, 2024, from Nasdaq, Inc. informing the Company that it had regained compliance with Nasdaq Listing Rule 5250(c)(1). The Company filed the following on October&nbsp;29, 2024, with the Securities and Exchange Commission: (i) restated audited consolidated financial statements for the fiscal years ended December&nbsp;31, 2023 and 2022 and restated quarterly financial statements for the periods ended March&nbsp;31, 2023; June&nbsp;30, 2023; September&nbsp;30, 2023; March&nbsp;31, 2022, June&nbsp;30, 2022, and September&nbsp;30, 2022 on Form 10-K/A; (ii) restated quarterly consolidated financial statements for the three months ended March&nbsp;31, 2024 on Form 10-Q/A; and (iii) quarterly financial statements for the three and six months ended June&nbsp;30, 2024 on Form 10-Q. The letter from Nasdaq noted that the matter is now closed.

Cellectar Biosciences Received A Letter From Nasdaq Informing The Company That It Had Regained Compliance With Nasdaq Listing Rule 5250(c)(1)

Oppenheimer analyst Jeff Jones reiterates Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) with a Outperform and maintains $14 price target.

Price Target

Reiteration

Analyst Ratings

Oppenheimer Reiterates Outperform on Cellectar Biosciences, Maintains $14 Price Target

<ul>
<li>The Notice indicated that the Company is not in compliance with the periodic financial report filing requirement set forth in Nasdaq Listing Rule 5250(c)(1) as a result of the Company&#39;s delay in filing its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the &quot;Second Quarter&nbsp;10-Q&quot;), by the applicable due date.</li>
<li>The delay in filing the&nbsp;Second Quarter&nbsp;10-Q is a result of the Company&#39;s need to restate certain previously filed financial statements.</li>
</ul>

Reported Friday, Cellectar Biosciences Announces Plan To Restate Financials, Delays 10-Q Filing, And Receives Nasdaq Non-Compliance Notification

Earnings

Guidance

Health Care

Cellectar Biosciences Says Its Cash Balance Of $25.9M As Of June 30, 2024, When Combined With The $19.4M Raised In July, Is Adequate To Fund Its Basic Budgeted Operations Into The Second Quarter Of 2025

U.S. stocks traded slightly higher toward the end of trading, with the Dow Jones gaining by more than 50 points on Tuesday.
The Dow traded up 0.17% to 40,483.92 while the NASDAQ rose 0.20% to 18,043.64. The S&amp;P 500 also rose, gaining, 0.14% to 5,572.07.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/07/39904913/how-to-earn-500-a-month-from-alphabet-stock-ahead-of-q2-earnings-report">How To Earn $500 A Month From Alphabet Stock Ahead Of Q2 Earnings Report</a>
Leading and Lagging Sectors Consumer discretionary shares jumped by 0.5% on Tuesday.
In trading on Tuesday, energy shares fell by 1.4%.
Top Headline
Coca-Cola Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) reported better-than-expected second-quarter results and raised its guidance.
The company reported second-quarter FY24 sales growth of 3% year-on-year to $12.4 billion, beating the analyst consensus estimate of $11.753 billion. Adjusted EPS of 84 cents beat the consensus estimate of 81 cents.
Coca-Cola raised its FY24 organic revenue growth outlook from 8% – 9% to 9% – 10%. KO raised comparable currency neutral EPS growth outlook from 11% – 13% to 13% – 15%.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Azitra, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#NYSE">AZTR</a>) shares shot up 326% to $6.91 after the company announced that the U.S. Patent and Trademark Office granted it U.S. Patent No. 12,036,248 for the treatment of atopic dermatitis.</li>
<li>Shares of Adial Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) got a boost, surging 39% to $1.47 after the company announced it advanced into the second cohort and commenced dosing for the Pharmacokinetics Study of AD04 for alcohol use disorder.</li>
<li>Frequency Electronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEIM#NASDAQ">FEIM</a>) shares were also up, gaining 33% to $13.48 following fourth-quarter earnings. Also, the company declared a $1.00 special cash dividend.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Jaguar Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares dropped 57% to $1.84 after the company announced its phase 3 OnTarget trial results for Crofelemer did not meet its primary endpoint.</li>
<li>Shares of TransCode Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) were down 62% to $0.30 after the company priced $3 million public offering of 10 million common shares at $0.30 per share.</li>
<li>Cellectar Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) was down, falling 19% to $2.4502. The company announced results from its CLOVER WaM pivotal study evaluating iopofosine I 131.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/news/24/07/39905767/wall-streets-most-accurate-analysts-give-their-take-on-3-tech-and-telecom-stocks-with-over-3-dividen">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Tech And Telecom Stocks With Over 3% Dividend Yields </a>
Commodities In commodity news, oil traded down 1.6% to $77.12 while gold traded up 0.5% at $2,407.20.
Silver traded down 0.1% to $29.305 on Tuesday, while copper fell 0.9% to $4.1605.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 climbed 0.13%, Germany's DAX gained 0.82% and France's CAC 40 fell 0.31%. Spain's IBEX 35 Index rose 0.62%, while London's FTSE 100 fell 0.38%.
Asia Pacific Markets
Asian markets closed lower on Tuesday, with Japan's Nikkei 225 falling 0.01%, Hong Kong's Hang Seng Index falling 0.94%, China's Shanghai Composite Index declining 1.65% and India's S&amp;P BSE Sensex declining 0.09%.
The annual inflation rate in Hong Kong rose to 1.5% in June from 1.2% in the prior month. The People&#8217;s Bank of China slashed one-year loan prime rate by 10bps to 3.35%.
Economics
<ul>
<li>The composite manufacturing index in the US Fifth District fell to -17 in July compared to a reading of -10 in June.</li>
<li>Existing home sales declined by 5.4% from the prior month to an annualized rate of 3.89 million units for June.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/07/39906268/this-coinbase-global-analyst-turns-bullish-here-are-top-5-upgrades-for-tuesday">This Coinbase Global Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday</a>

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ADIL

AZTR

FEIM

JAGX

RNAZ

Gold Moves Higher; Coca-Cola Increases FY24 Forecast

Shares of Comcast Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) fell sharply during Tuesday's session after the company reported worse-than-expected <a href="https://www.benzinga.com/news/earnings/24/07/39908857/comcasts-q2-earnings-studios-and-theme-parks-pull-revenue-lower-broadband-and-video-subs-fall">second-quarter sales results</a>.
Comcast reported second-quarter revenue decline of 2.7% year-over-year to $29.69 billion, missing the analyst consensus estimate of $30.02 billion.The company reported adjusted EPS of $1.21, beating analyst consensus estimates of $1.12, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Comcast shares declined 6.1% to $37.12 on Tuesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Azitra, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#NYSE">AZTR</a>) shares jumped 529% to $10.19 after the company announced that the U.S. Patent and Trademark Office granted it U.S. Patent No. 12,036,248 for the treatment of atopic dermatitis.</li>
<li>Adial Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) jumped 148% to $2.6299 after the company announced it advanced into the second cohort and commenced dosing for the Pharmacokinetics Study of AD04 for alcohol use disorder.</li>
<li>Salarius Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) gained 111% to $3.2540.</li>
<li>Agape ATP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares climbed 67% to $0.2390.</li>
<li>Smart for Life, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMFL#NASDAQ">SMFL</a>) rose 45% to $2.7950.</li>
<li>Dermata Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRMA#NASDAQ">DRMA</a>) gained 43% to $2.41.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) jumped 36.5% to $4.60.</li>
<li>Volato Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#NYSE">SOAR</a>) gained 33.5% to $0.6385 after jumping around 20% on Monday.</li>
<li>Frequency Electronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEIM#NASDAQ">FEIM</a>) shares climbed 30% to $13.11 following fourth-quarter earnings. Also, the company declared a $1.00 special cash dividend.</li>
<li>Mammoth Energy Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TUSK#NASDAQ">TUSK</a>) gained 26% to $4.42 after the company announced its subsidiary, Cobra Acquisitions, entered into a release and settlement agreement with the Puerto Rico Electric Power Authority.</li>
<li>iClick Interactive Asia Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLK#NASDAQ">ICLK</a>) rose 23.5% to $2.05.</li>
<li>1847 Holdings LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NYSE">EFSH</a>) jumped 19.3% to $2.90.</li>
<li>Milestone Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLSS#NYSE">MLSS</a>) gained 17.5% to $1.02 after the company announced the Medicare price assignment for its CompuFlo Epidural System.</li>
<li>Staffing 360 Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAF#NASDAQ">STAF</a>) gained 16% to $2.1493.</li>
<li>Kiniksa Pharmaceuticals International, plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNSA#NASDAQ">KNSA</a>) rose 16% to $24.81 after the company reported better-than-expected second-quarter sales results and raised its FY24 net product revenue guidance.</li>
<li>Aeva Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEVA#NYSE">AEVA</a>) gained 15.1% to $3.6713.</li>
<li>Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) jumped 12.7% to $333.02 following second-quarter earnings.</li>
<li>NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) gained 11.8% to $12.34.</li>
<li>PureCycle Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>) rose 11.8% to $6.90.</li>
<li>MSCI Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) gained 11.1% to $561.96 following better-than-expected second-quarter financial results.</li>
<li>Crown Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) rose 8.5% to $84.04 after the company reported better-than-expected second-quarter earnings and raised its FY24 EPS guidance above estimates.</li>
<li>MakeMyTrip Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) gained 8% to $96.75 following better-than-expected quarterly earnings.</li>
<li>Owens &amp; Minor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) gained 8% to $16.51 as the company released preliminary second quarter 2024 financial results and signed a definitive agreement to acquire Rotech Healthcare for $1.36 billion in cash.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) shares surged 8% to $8.15. Mesoblast recently started enrollment in Phase 3 trial of Rexlemestrocel-L for chronic low back pain.</li>
<li>Pentair plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) climbed 7.7% to $86.19 after the company reported better-than-expected second quarter financial results and revised its FY24 adjusted EPS guidance above estimates.</li>
<li>Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) gained 7.4% to $269.35 after the company reported better-than-expected second quarter earnings.</li>
<li>GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) gained 6.4% to $173.21 after the company reported better-than-expected second quarter adjusted EPS and raised its FY24 outlook.</li>
<li>SAP SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) rose 6% to $0.2390 after the company reported second-quarter financial results.</li>
<li>Zions Bancorporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) gained 5.4% to $52.12 after posting better-than-expected quarterly results on Monday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Jaguar Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares dipped 65% to $1.50 after the company announced its phase 3 OnTarget trial results for Crofelemer did not meet its primary endpoint.</li>
<li>TransCode Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) dipped 62.2% to $0.2999 after the company announced a proposed public offering.</li>
<li>Fly-E Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYE#NASDAQ">FLYE</a>) tumbled 59.2% to $2.60.</li>
<li>MIRA Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) shares dipped 50.3% to $2.4636. MIRA Pharmaceuticals shares jumped 627% on Monday after the company announced new preclinical study results for its novel oral ketamine analog, Ketamir-2.</li>
<li>CareMax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) shares fell 38.3% to $3.1851 after surging 228% on Monday.</li>
<li>Selina Hospitality PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNA#NASDAQ">SLNA</a>) dipped 32.4% to $0.0250.</li>
<li>PS International Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) fell 32.2% to $1.83.</li>
<li>Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) fell 31.1% to $0.3440.</li>
<li>Cellectar Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) dipped 26.2% to $2.23. The company announced results from its CLOVER WaM pivotal study evaluating iopofosine I 131.</li>
<li>Crown LNG Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGBS#NASDAQ">CGBS</a>) fell 23% to $0.77.</li>
<li>Castellum, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTM#NYSE">CTM</a>) fell 20% to $0.1594. Castellum recently announced a new strategic alliance with Krilla Kaleiwahea.</li>
<li>Netcapital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCPL#NASDAQ">NCPL</a>) fell 17.3% to $0.0926 after gaining around 8% on Monday.</li>
<li>Medpace Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) shares declined 16.6% to $364.00 after the company reported mixed second-quarter financial results and narrowed its FY24 revenue guidance with its midpoint below estimates.</li>
<li>Fitell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) dipped 15.2% to $16.48.</li>
<li>United Parcel Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) fell 13.2% to $126.04 after the company reported worse-than-expected quarterly financial results.</li>
<li>Nukkleus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>) shares fell 10% to $0.4479 after gaining over 55% on Monday.</li>
<li>NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) shares fell 9.5% to $256.55 following mixed second-quarter earnings.</li>
<li>New Fortress Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>) dipped 9.2% to $23.28.</li>
<li>PACCAR Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>) fell 8.4% to $99.92 after the company reported worse-than-expected second-quarter financial results.</li>
<li>A. O. Smith Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOS#NYSE">AOS</a>) declined 8.4% to $81.30. The company reported second-quarter financial results.</li>
<li>WEBTOON Entertainment Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBTN#NASDAQ">WBTN</a>) dipped 7.7% to $22.00.</li>
<li>Polaris Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>) declined 7.2% to $76.23 after the company reported worse-than-expected second-quarter financial results and cut its guidance.</li>
<li>Archrock, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AROC#NYSE">AROC</a>) shares declined 6.9% to $21.76. Archrock commenced public offering of 11 million shares of its common stock and announced plans to acquire Total Operations and Production Services for $983 million in cash and stock.</li>
<li>General Motors Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) fell 6.1% to $46.52 after the company reported second-quarter financial results. Also, the company announced that it delayed its 2024 Buick EV and pushed its EV pickup plant opening to 2026.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39907957/microsoft-to-rally-around-10-here-are-10-top-analyst-forecasts-for-monday">Microsoft To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>

AEVA

AROC

ATPC

CGBS

CMAX

CMCSA

DRMA

EFSH

FLYE

FTEL

ICLK

KNSA

MEDP

MESO

MIRA

MLSS

MMYT

MSCI

NCPL

NUKK

NXPI

PCAR

PSIG

SLNA

SLRX

SMFL

SOAR

SPOT

STAF

TUSK

WBTN

XCUR

ZION

Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Tuesday.
The Dow traded up 0.09% to 40,452.70 while the NASDAQ rose 0.62% to 18,119.84. The S&amp;P 500 also rose, gaining, 0.32% to 5,582.32.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/07/39904913/how-to-earn-500-a-month-from-alphabet-stock-ahead-of-q2-earnings-report">How To Earn $500 A Month From Alphabet Stock Ahead Of Q2 Earnings Report</a>
Leading and Lagging Sectors Consumer discretionary shares jumped by 1% on Tuesday.
In trading on Tuesday, energy shares fell by 1.4%.
Top Headline
GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) reported better-than-expected second-quarter earnings and raised its FY24 outlook.
GE Aerospace reported second-quarter 2024 adjusted revenue growth of 4% year-over-year to $8.22 billion, missing the consensus of $8.462 billion. Adjusted EPS was $1.20 (+61% YoY), beating the consensus of 99 cents.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Azitra, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#NYSE">AZTR</a>) shares shot up 455% to $9.00 after the company announced that the U.S. Patent and Trademark Office granted it U.S. Patent No. 12,036,248 for the treatment of atopic dermatitis.</li>
<li>Shares of Adial Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) got a boost, surging 62% to $1.7150 after the company announced it advanced into the second cohort and commenced dosing for the Pharmacokinetics Study of AD04 for alcohol use disorder.</li>
<li>Frequency Electronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEIM#NASDAQ">FEIM</a>) shares were also up, gaining 30% to $13.15 following fourth-quarter earnings. Also, the company declared a $1.00 special cash dividend.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Jaguar Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares dropped 64% to $1.5387 after the company announced its phase 3 OnTarget trial results for Crofelemer did not meet its primary endpoint.</li>
<li>Shares of TransCode Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) were down 62% to $0.2997 after the company priced $3 million public offering of 10 million common shares at $0.30 per share.</li>
<li>Cellectar Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) was down, falling 24% to $2.2850. The company announced results from its CLOVER WaM pivotal study evaluating iopofosine I 131.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/news/24/07/39905767/wall-streets-most-accurate-analysts-give-their-take-on-3-tech-and-telecom-stocks-with-over-3-dividen">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Tech And Telecom Stocks With Over 3% Dividend Yields</a>
Commodities In commodity news, oil traded down 2% to $76.86 while gold traded up 0.4% at $2,405.00.
Silver traded down 0.5% to $29.19 on Tuesday, while copper fell 0.9% to $4.16.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 climbed 0.07%, Germany's DAX gained 0.68% and France's CAC 40 fell 0.33%. Spain's IBEX 35 Index rose 0.57%, while London's FTSE 100 fell 0.43%.
Asia Pacific Markets
Asian markets closed lower on Tuesday, with Japan's Nikkei 225 falling 0.01%, Hong Kong's Hang Seng Index falling 0.94%, China's Shanghai Composite Index declining 1.65% and India's S&amp;P BSE Sensex declining 0.09%.
The annual inflation rate in Hong Kong rose to 1.5% in June from 1.2% in the prior month. The People&#8217;s Bank of China slashed one-year loan prime rate by 10bps to 3.35%.
Economics
The composite manufacturing index in the US Fifth District fell to -17 in July compared to a reading of -10 in June.
Existing home sales declined by 5.4% from the prior month to an annualized rate of 3.89 million units for June.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39906268/this-coinbase-global-analyst-turns-bullish-here-are-top-5-upgrades-for-tuesday">This Coinbase Global Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday</a> </li>
</ul>

Crude Oil Down 2%; GE Aerospace Earnings Top Views

Cellectar Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) stock is trading lower Tuesday after the company shared results from its CLOVER WaM pivotal study.
The study evaluated iopofosine I 131, a targeted radiotherapeutic candidate, for relapsed/refractory Waldenstrom&#8217;s macroglobulinemia (WM) — a type of cancer that begins in <a href="https://www.benzinga.com/pressreleases/24/07/g39901569/cellectar-biosciences-iopofosine-i-131-exceeds-primary-endpoint-in-waldenstroms-macroglobulinemia-" target="_blank" rel="noreferrer noopener">the white blood cells</a>.
As of May 31, the CLOVER WaM study&#8217;s results had an overall response rate (ORR) of 80% and a major response rate (MRR) of 56.4%. Results exceeded the agreed-upon primary endpoint of a 20% MRR.
The median number of prior lines of therapy was four, with approximately 27% of patients refractory to all available therapies and 40% of patients dual-class refractory.
In January, when the company reported early data, the CLOVER WaM study showed MRR of 61%, ORR of 75.6% in evaluable patients, and 100% <a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36536874/why-is-cancer-focused-cellectar-biosciences-stock-trading-higher-today" rel="noreferrer noopener">experienced disease control</a>.&nbsp;
The comparable ORRs were observed across all disease subgroups, including: MYD88-wt (81%; n=16), P53-mutated (80%; n=5), and clinical patient cohorts including post-BTKi (72%; n=39), as well as dual-class (59%; n=22), and triple-class (53%; n=15) refractory patients.
Secondary endpoints of disease control rate (98.2%) and duration of response (DoR) presented evidence that iopofosine provided durable clinical benefit across all response categories.
The median DoR in patients achieving major response and overall response were not reached as of the data cutoff, with 78% and 72% remaining free from disease progression at 18 months, respectively.
The company plans to file an FDA marketing application in the fourth quarter of 2024.
Iopofosine I 131 was well tolerated and its toxicity profile was consistent with the company&#8217;s previously reported safety data.
Unlike other cancer therapies, patients on iopofosine did not experience any cardiovascular, renal, or liver toxicities.
The most commonly reported treatment-emergent adverse events were hematologic in nature (thrombocytopenia, neutropenia and anemia) and were predictable and manageable.
All patients recovered from cytopenias within a few weeks post nadir.
The company says that CLOVER WaM is the first and largest WM <a target="_blank" href="https://clinicaltrials.gov/study/NCT02952508" rel="noreferrer noopener">study</a> to date in a highly refractory patient population.
Price Action: CLRB stock was down 24.83% at $2.27 at last check Tuesday. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/24/07/39904625/exclusive-milestone-scientific-announces-medicare-price-assignment-for-compuflo-epidural-system-for" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Milestone Scientific Announces Medicare Price Assignment For CompuFlo Epidural System For Back Pain Covering Additional US States</a>.</li>
</ul>

Movers

Cancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer Study

WIIM

Cellectar Biosciences shares are trading lower. The company announced results from its CLOVER WaM pivotal study evaluating iopofosine I 131.

&nbsp;&nbsp; &nbsp;56.4% major response rate exceeded 20% primary endpoint 
&middot;&nbsp;&nbsp; &nbsp;98.2% disease control rate achieved in heavily pretreated patients 
&middot;&nbsp;&nbsp; &nbsp;Responses shown in difficult-to-treat, high-needs patient populations with approximately 27% of patients refractory to all available therapies and 40% dual-class refractory (BTKi and rituximab)

Cellectar Biosciences' Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom's Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months

Cellectar Biosciences shares are trading higher after the company announced the exercise of Tranche B warrants and purchase of new warrants.

Cellectar Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the majority of Tranche B warrants issued under its September 2023 private placement have been exercised for Series E preferred stock, convertible into the company&#39;s common stock, by the participants of the previous financing, led by Rosalind Advisors, in exchange for a reduced, as-converted common stock price of&nbsp;$2.52&nbsp;and the purchase of new warrants. The exercised Tranche B warrants and newly purchased warrants will generate gross proceeds of approximately&nbsp;$19.4 million. The new warrants purchased by investors have the potential to generate up to an additional&nbsp;$73.3 million&nbsp;in gross proceeds, if exercised.

Cellectar Biosciences Generates $19.4M, Potential for Additional $73.3M Through New Warrants

Contracts

Cellectar Biosciences Partners With City Of Hope Cancer Center To Focus On Clinical Development Of Cellectar's Lead Radioconjugate Asset, Iopofosine I 131, In Mycosis Fungoides; Initiation Is Planned For Late 2024 Or Early 2025

Offerings

Cellectar Biosciences Files $300M Mixed Securities Shelf

Cellectar Biosciences' Cash and Cash Equivalents, As of March 31, 2024, Was $40M That Is Expected To Provide Cash Runway Into Fourth Quarter Of 2024

Cellectar Biosciences Q1 2024 GAAP EPS $(0.74) Misses $(0.56) Estimate

Roth MKM analyst Jonathan Aschoff maintains Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) with a Buy and raises the price target from $20 to $28.

Roth MKM Maintains Buy on Cellectar Biosciences, Raises Price Target to $28

Oppenheimer analyst Jeff Jones reiterates Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) with a Outperform and raises the price target from $11 to $12.

Oppenheimer Reiterates Outperform on Cellectar Biosciences, Raises Price Target to $12

Warning: CLRB is at high risk of performing badly

Cellectar Biosciences (CLRB) announced it received a letter dated October 31 from Nasdaq, informing the company that it had regained compliance wit...

Cellectar Biosciences regains compliance with Nasdaq

Cellectar Biosciences (CLRB) announced the signing of a strategic supply agreement with NorthStar Medical Radioisotopes, LLC, for the procurement o...

Cellectar Biosciences signs strategic supply agreement with NorthStar

Press Releases

Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024

UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024

Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update

Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq

Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's Macroglobulinemia

Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q

Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024

Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer

Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225

Comments

Cellectar Biosciences

Vendite allo scoperto

Cellectar Biosciences (NASDAQ:CLRB) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO